https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46762 Wed 30 Nov 2022 10:19:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18363 Wed 11 Apr 2018 10:06:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28587 Tue 08 Jan 2019 15:13:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:557 Thu 25 Jul 2013 09:10:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7315 Sat 24 Mar 2018 10:44:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9456 0.05). There was a significant correlation between the greatest percentage fall in forced expiratory volume in 1 s (FEV₁)(r=0.6, P<0.0001), the dose–response slope (r=0.73), cumulative dose (r=0.55) and PD15 (r=0.46) for mannitol and hypertonic saline. The greatest percentage fall in FEV₁to mannitol was less in non-eosinophilic asthma. There was a lower total cell count in mannitol vs. hypertonic-saline-induced sputum. However, sputum eosinophils and neutrophils were not significantly different. Using mannitol, a higher proportion of subjects were classified as having eosinophilic asthma. There were no differences in IL-8, neutrophil elastase or matrix-metalloproteinase 9 concentrations in sputum samples induced with mannitol or hypertonic saline. Conclusion: We conclude that mannitol can be used to induce good-quality sputum, useful for analysis of inflammatory mediators and for predicting the inflammatory phenotype in asthma.]]> Sat 24 Mar 2018 08:41:08 AEDT ]]>